Literature DB >> 12595488

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.

Samer Aboudola1, Karen L Kotloff, Lorraine Kyne, Michel Warny, Eoin C Kelly, Stavros Sougioultzis, Paul J Giannasca, Thomas P Monath, Ciarán P Kelly.   

Abstract

There is a strong association between serum antibody responses to toxin A and protection against Clostridium difficile diarrhea. A parenteral C. difficile toxoid vaccine induced very-high-level responses to anti-toxin A immunoglobulin G (IgG) in the sera of healthy volunteers. After vaccination, the concentrations of anti-toxin A IgG in the sera of all 30 recipients exceeded the concentrations that were associated with protection in previous clinical studies. Furthermore, the median concentration of serum anti-toxin A IgG in the test group was 50-fold higher than the previous threshold. These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595488      PMCID: PMC148861          DOI: 10.1128/IAI.71.3.1608-1610.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain.

Authors:  E J Kuijper; J de Weerdt; H Kato; N Kato; A P van Dam; E R van der Vorm; J Weel; C van Rheenen; J Dankert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-08       Impact factor: 3.267

2.  Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

Authors:  K L Kotloff; S S Wasserman; G A Losonsky; W Thomas; R Nichols; R Edelman; M Bridwell; T P Monath
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

3.  Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile.

Authors:  A P Limaye; D K Turgeon; B T Cookson; T R Fritsche
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.

Authors:  J Salcedo; S Keates; C Pothoulakis; M Warny; I Castagliuolo; J T LaMont; C P Kelly
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

5.  Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay.

Authors:  S Johnson; S A Kent; K J O'Leary; M M Merrigan; S P Sambol; L R Peterson; D N Gerding
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

6.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

7.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

Review 8.  Clostridium difficile.

Authors:  L Kyne; R J Farrell; C P Kelly
Journal:  Gastroenterol Clin North Am       Date:  2001-09       Impact factor: 3.806

9.  Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

Authors:  M Warny; J P Vaerman; V Avesani; M Delmée
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

10.  Prospects for a vaccine for Clostridium difficile.

Authors:  L Kyne; C P Kelly
Journal:  BioDrugs       Date:  1998-09       Impact factor: 5.807

View more
  41 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Recognition and prevention of hospital-associated enteric infections in the intensive care unit.

Authors:  Linda D Bobo; Erik R Dubberke
Journal:  Crit Care Med       Date:  2010-08       Impact factor: 7.598

Review 3.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 4.  Pathogenesis and treatment of Clostridium difficile infection.

Authors:  I Tonna; P D Welsby
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

Review 5.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease.

Authors:  Séverine Péchiné; Claire Janoir; Anne Collignon
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

7.  An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Authors:  Scott M Baliban; Amanda Michael; Berje Shammassian; Shikata Mudakha; Amir S Khan; Simon Cocklin; Isaac Zentner; Brian P Latimer; Laurent Bouillaut; Meredith Hunter; Preston Marx; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

Review 8.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

9.  Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.

Authors:  Jinfu Xie; Julie Zorman; Lani Indrawati; Melanie Horton; Keri Soring; Joseph M Antonello; Yuhua Zhang; Susan Secore; Matthew Miezeiewski; Su Wang; Anthony D Kanavage; Julie M Skinner; Irene Rogers; Jean-Luc Bodmer; Jon H Heinrichs
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

10.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.